Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Parabilis Medicines (Nasdaq: PBLS) reported a third-quarter 2026 net loss of $44.491 million while advancing zolucatetide toward Phase 3 development. Revenue was $2.114 million versus none a year earlier; net loss increased from $33.475 million. Cash, cash equivalents and marketable securities totaled $1.1 billion, expected to fund operations into 2030.
In Phase 1/2 desmoid tumor data, the response rate was 72.2% (13/18) among patients evaluable at 32 weeks starting at ≥450 mg. No treatment-related adverse events caused discontinuation among 76 patients. Following FDA alignment on dose, regimen and design, Parabilis plans to start PEDESTAL Phase 3 in the first half of 2027, with results anticipated in 2029. It initiated a familial adenomatous polyposis dose-ranging cohort and entered a colorectal cancer combination-study collaboration with Revolution Medicines.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cash and securities reached $1.1 billion versus $27.7 million at year-end 2025; operations funded into 2030 are expected.
- Moderate pointDesmoid tumor response rate was 72.2% (13/18) at 32 weeks among evaluable patients starting at ≥450 mg.
- Moderate pointFDA alignment covered Phase 3 dose, regimen and trial design for desmoid tumors.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Parabilis plans PEDESTAL initiation in first-half 2027, with topline results anticipated in 2029.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Revolution Medicines collaboration will evaluate zolucatetide, zoldonrasib and cetuximab in previously treated RAS G12D mutant colorectal cancer.
16 minor points
- Minor pointThird-quarter revenue reached $2.114 million, versus none in the comparable 2025 quarter.
- Minor pointDesmoid disease control reached 100%, with no progression among all 46 response-evaluable patients starting at ≥450 mg.
- Minor pointSafety data in 76 patients showed no discontinuations due to treatment-related adverse events.
- Minor pointChina desmoid Phase 1/2 trial initiated to support planned inclusion in global PEDESTAL.
- Minor pointFamilial adenomatous polyposis dose-ranging cohort initiated to identify the optimal dose and regimen.
- Minor point. Forward-looking: it has not happened yet and may not happen.Parabilis anticipates first-quarter 2027 FAP translational and additional patient data, following polyp reductions in two patients.
- Minor point. Forward-looking: it has not happened yet and may not happen.Parabilis anticipates first-half 2027 additional craniopharyngioma patient data, following early antitumor activity in three patients.
- Minor point. Forward-looking: it has not happened yet and may not happen.Parabilis anticipates first-quarter 2027 liver cancer data, following early activity in a heavily pretreated patient.
- Minor pointPreclinical combination data showed enhanced tumor growth inhibition with zolucatetide and zoldonrasib in a colorectal cancer model.
- Minor pointParabilis continued preclinical ERG, allosteric ARON and β-catenin degrader programs and research with Regeneron.
- Minor pointThird-quarter interest income rose to $10.369 million from $0.711 million a year earlier.
- Minor pointThird-quarter interest expense fell to $0.124 million from $0.398 million a year earlier.
- Minor pointTerm loan, net of discount, declined to $2 million from $13.077 million at year-end 2025.
- Minor pointNine-month revenue reached $2.262 million, versus none in the comparable 2025 period.
- Minor pointThird-quarter basic and diluted loss per common share narrowed to $0.36 from $21.66 a year earlier.
- Minor pointNine-month basic and diluted loss per common share narrowed to $3.51 from $67.78 a year earlier.
Negative
- Moderate pointThird-quarter net loss widened to $44.491 million from $33.475 million a year earlier.
- Moderate pointThird-quarter research and development expense increased to $45.597 million from $28.199 million a year earlier.
- Minor pointThird-quarter general and administrative expense increased to $11.253 million from $6.646 million a year earlier.
- Minor pointNine-month net loss widened to $142.270 million from $106.611 million a year earlier.
- Minor pointNine-month research and development expense increased to $122.727 million from $92.230 million a year earlier.
4 minor points
- Minor pointNine-month general and administrative expense increased to $32.610 million from $19.376 million a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.Parabilis will sponsor and conduct the Revolution Medicines study, with trial costs shared equally.
- Minor pointNine-month fair-value expense on a simple agreement for future equity was $5.556 million, versus none a year earlier.
- Minor pointNine-month convertible preferred stock down-round generated a $7.875 million deemed dividend, versus none a year earlier.
News Explained
Parabilis has entered a clinical collaboration with Revolution Medicines to test zolucatetide with zoldonrasib and cetuximab in previously treated RAS G12D mutant MSS colorectal cancer; Parabilis will sponsor and run the study, Revolution will supply zoldonrasib, and the parties will share trial costs equally.
Details
Market move: PBLS -6.61% in the Nov 12 session. 3Q26 earnings report
On Nov 12, the day this news came out, PBLS closed 6.61% below the previous close. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner recorded 16 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 12 session.
Key Figures
- Objective response rate
- 72.2% (13/18 patients)
- Desmoid tumors; 32-week landmark; starting dose of ≥450 mg
- Disease control rate
- 100% (46 patients)
- Desmoid tumors; response-evaluable patients receiving a starting dose of ≥450 mg
- PEDESTAL Phase 3 initiation
- First half of 2027
- Planned randomized, double-blind registrational trial
- PEDESTAL topline results
- 2029
- Anticipated results
- Cash, cash equivalents and marketable securities
- $1.1 billion
- As of September 30, 2026; expected to fund operations into 2030
- Revenue
- $2.1 million
- Quarter ended September 30, 2026; compared with no revenue in the prior-year period
- Research and development expenses
- $45.6 million
- Quarter ended September 30, 2026; compared with $28.2 million in the prior-year period
- Net loss
- $44.5 million
- Quarter ended September 30, 2026; compared with $33.5 million in the prior-year period
Previous Earnings Reports
-
Q2 reported a $52.5 million net loss and $39.4 million R&D expense amid clinical investment.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
objective response rate medical
disease control rate medical
double-blind technical
mitogen-activated protein kinase medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a
Reached alignment with the U.S. FDA on dose, regimen and trial design for upcoming PEDESTAL Phase 3 registrational trial in desmoid tumors
Initiated a dose-ranging clinical study of zolucatetide in familial adenomatous polyposis (FAP)
Entered into a clinical collaboration with Revolution Medicines to evaluate zolucatetide in combination with zoldonrasib and cetuximab in patients with previously treated RAS G12D mutant microsatellite stable metastatic colorectal cancer (MSS CRC)
Ended the third quarter with
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today reported financial results and business updates for the third quarter ended September 30, 2026.
“With each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful difference for patients across multiple diseases,” said Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President of Parabilis Medicines. “The updated results presented at ESMO further reinforce our confidence in the depth and consistency of desmoid tumor responses, alongside a favorable safety and tolerability profile. With our Phase 3 dosing, regimen and trial design aligned with the FDA, we are well positioned to initiate PEDESTAL in the first half of 2027, bringing us closer to delivering a potentially transformative treatment for patients with desmoid tumors.”
Dr. Mammen continued, “We are also continuing to deliver on zolucatetide’s potential to become a pipeline in a product, advancing development in FAP, adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and other Wnt-driven diseases, while pursuing a scientifically grounded combination approach in MSS CRC through our collaboration with Revolution Medicines. In parallel, we are selectively advancing a broader pipeline of programs against other historically undruggable targets. The progress across our portfolio continues to strengthen our conviction in the ability of our HeliconTM platform to repeatedly translate breakthrough science into medicines that can meaningfully improve patients’ lives.”
Recent Business Highlights and Anticipated Milestones
Continued Advancement of Zolucatetide
Desmoid tumors
- Presented compelling clinical data from a June 22, 2026, data cut of the ongoing Phase 1/2 trial of zolucatetide at the European Society for Medical Oncology (ESMO) Congress 2026, demonstrating:
- An objective response rate (ORR) of
72.2% (13/18) among patients evaluable at the 32-week landmark who received a starting dose of ≥450 mg - A disease control rate (DCR) of
100% , with no disease progression, across all 46 response-evaluable patients receiving a starting dose of ≥450 mg - A favorable safety and tolerability profile now shown in 76 patients, with no treatment discontinuations due to treatment-related adverse events (TRAEs)
- An objective response rate (ORR) of
- Reached alignment with the U.S. Food and Drug Administration (FDA) on a global Phase 3 trial design; plan to initiate the randomized, double-blind PEDESTAL Phase 3 registrational trial in the first half of 2027 with topline results anticipated in 2029
- Selected for an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting in November 2026, featuring data from the June 22, 2026, data cut
- Initiated a Phase 1/2 clinical trial of zolucatetide in patients with desmoid tumors in China to support the planned inclusion of patients in China in the global PEDESTAL Phase 3 registrational trial
Familial adenomatous polyposis
- Initiated a dose-ranging clinical cohort as part of the ongoing Phase 1/2 trial to evaluate zolucatetide in patients with FAP and identify the optimal dose and regimen
- Anticipate disclosing translational data demonstrating on-target activity at a medical meeting in the first quarter of 2027
- Anticipate disclosing clinical data from additional patients with FAP in the first quarter of 2027, building on compelling early observations of duodenal polyp reductions in two patients
Adamantinomatous craniopharyngioma
- Anticipate disclosing updated clinical data from additional patients with ACP in the first half of 2027, building on encouraging early antitumor activity in three patients
Hepatocellular carcinoma and additional Wnt/β-catenin-driven tumors
- Anticipate disclosing additional clinical data in HCC at a medical meeting in the first quarter of 2027, building on evidence of early activity in a heavily pretreated patient
- Continue evaluating zolucatetide across additional Wnt/β-catenin-driven tumor types as part of the ongoing Phase 1/2 clinical trial
Clinical collaboration with Revolution Medicines in RAS G12D mutant MSS CRC
- Entered into a clinical collaboration with Revolution Medicines (RevMed) to evaluate zolucatetide in combination with RevMed’s zoldonrasib, an investigational, oral RAS(ON) G12D-selective covalent tri-complex inhibitor, and cetuximab, an EGFR inhibitor, in patients with previously treated RAS G12D mutant MSS CRC; Parabilis will sponsor and conduct the study, with RevMed supplying zoldonrasib and equally sharing the costs of the trial
- Supported by clinical translational data from the Phase 1/2 trial showing reciprocal upregulation of mitogen-activated protein kinase (MAPK) and downregulation of the Wnt pathway in patients with MSS CRC treated with zolucatetide, alongside a manageable safety and tolerability profile
- Also supported by preclinical data showing enhanced tumor growth inhibition when zolucatetide was combined with zoldonrasib in a CRC patient-derived xenograft model
Advancement of the Helicon Platform and Discovery Pipeline
- Continued advancing wholly owned preclinical programs, including ERG and allosteric ARON degraders in prostate cancer and a β-catenin degrader program, alongside ongoing research under the strategic collaboration with Regeneron to develop Antibody-Helicon Conjugates (AHCs) targeting intracellular proteins
Corporate Updates
- Appointed Craig L. Tendler, M.D., to the Board of Directors in August 2026, bringing extensive oncology drug development and regulatory experience
Upcoming Investor Conferences
- Announced that Mathai Mammen, M.D., Ph.D., Chairman, CEO and President, will deliver a company presentation at the Jefferies Global Healthcare Conference in London, UK, on Monday, November 16, 2026, at 12:30 p.m. GMT / 7:30 a.m. EST, and participate in a fireside chat at the Evercore ISI 9th Annual Healthcare Conference on Monday, November 30, 2026, at 3:50 p.m. EST; webcasts will be available at https://investors.parabilismed.com/
Third Quarter 2026 Financial Results
Cash position and runway: Cash, cash equivalents and marketable securities were
Revenue: Revenues for the quarter ended September 30, 2026, were
R&D expenses: Research and development expenses were
G&A expenses: General and administrative expenses were
Net loss: Net loss was
About Parabilis Medicines
Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The Company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The Company's lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and a range of other rare and common solid tumor indications. Beyond zolucatetide, Parabilis is pursuing a follow-on β-catenin degrader program and advancing additional Helicon-based programs focused on other challenging targets, including ERG and allosteric ARON in prostate cancer, where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of zolucatetide for the treatment of desmoid tumors, FAP, ACP, HCC, CRC and other rare, Wnt-driven tumors, including the initiation, timing, progress, results and future data releases of our ongoing and planned clinical trials; the expected initiation and timing of the Company’s planned Phase 3 registrational trial in desmoid tumors; the expected timing and results of the ongoing Phase 1/2 study in desmoid tumors; the expected enrollment and timing of certain clinical studies and patient cohorts in FAP, CRC and other Wnt-driven tumors; the expected timing and results of the Company’s preclinical development of its ERG degrader, ARON degrader and β-catenin degrader development candidates; the potential of the Company’s Helicon™ technology platform; expectations regarding the development of any future product candidates using the Company’s Helicon™ technology platform; expectations regarding the efficacy, tolerability and commercial potential of zolucatetide; and expectations for the Company’s uses of capital, expenses and financial results, including its cash runway into 2030.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could negatively affect the Company’s business, operating results, financial condition and stock value. Factors that could cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release include, without limitation: risks relating to the Company’s research and development activities; the Company’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; the Company’s ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining the Company’s intellectual property protections; and risks related to the competitive landscape for the Company’s product candidates; as well as other risks and uncertainties described in greater detail in “Risk Factors,” in the Company’s most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Contacts
Media Contact
Jessica Freifeld
media@parabilismed.com
Investor Contact
Tom Kotarakos
investors@parabilismed.com
| Parabilis Medicines, Inc | ||||||||
| Condensed Consolidated Balance Sheets (in thousands) (unaudited) | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 521,198 | $ | 27,711 | ||||
| Accounts receivable - related party | 443 | — | ||||||
| Marketable securities | 350,425 | — | ||||||
| Prepaid expenses and other current assets | 6,953 | 1,647 | ||||||
| Total current assets | 879,019 | 29,358 | ||||||
| Property and equipment, net | 9,506 | 6,715 | ||||||
| Restricted cash | 2,855 | 2,855 | ||||||
| Operating lease right-of-use assets | 34,291 | 39,360 | ||||||
| Marketable securities, non-current | 201,309 | — | ||||||
| Other assets | 4,262 | 2,532 | ||||||
| Total assets | $ | 1,131,242 | $ | 80,820 | ||||
| Liabilities, convertible preferred stock and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 20,209 | $ | 17,272 | ||||
| Accrued expenses and other current liabilities | 24,012 | 18,630 | ||||||
| Operating lease liabilities, current portion | 7,810 | 7,174 | ||||||
| Deferred revenue, current portion | 13,544 | — | ||||||
| Finance lease liabilities, current portion | 684 | 638 | ||||||
| Term loan, net of discount | 2,000 | 13,077 | ||||||
| Total current liabilities | 68,259 | 56,791 | ||||||
| Operating lease liabilities, net of current portion | 30,381 | 36,341 | ||||||
| Finance lease liabilities, net of current portion | 951 | 1,470 | ||||||
| Deferred revenue, net of current portion | 27,304 | — | ||||||
| Other liabilities | — | 2,742 | ||||||
| Total liabilities | 126,895 | 97,344 | ||||||
| Commitments and contingencies | ||||||||
| Convertible preferred stock | — | 509,971 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 12 | — | ||||||
| Non-voting common stock | — | — | ||||||
| Additional paid-in capital | 1,690,022 | 15,009 | ||||||
| Accumulated other comprehensive loss | (1,913 | ) | — | |||||
| Accumulated deficit | (683,774 | ) | (541,504 | ) | ||||
| Total stockholders’ equity (deficit) | 1,004,347 | (526,495 | ) | |||||
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $ | 1,131,242 | $ | 80,820 | ||||
| Parabilis Medicines, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Collaboration revenue | $ | 671 | $ | — | $ | 819 | $ | — | ||||||||
| Collaboration revenue - related party | 1,443 | — | 1,443 | — | ||||||||||||
| Total revenue | 2,114 | — | 2,262 | — | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 45,597 | 28,199 | 122,727 | 92,230 | ||||||||||||
| General and administrative | 11,253 | 6,646 | 32,610 | 19,376 | ||||||||||||
| Total operating expenses | 56,850 | 34,845 | 155,337 | 111,606 | ||||||||||||
| Loss from operations | (54,736 | ) | (34,845 | ) | (153,075 | ) | (111,606 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 10,369 | 711 | 16,987 | 3,017 | ||||||||||||
| Interest expense | (124 | ) | (398 | ) | (626 | ) | (1,193 | ) | ||||||||
| Sublease income - related party | — | 1,057 | — | 3,171 | ||||||||||||
| Change in fair value of simple agreement for future equity | — | — | (5,556 | ) | — | |||||||||||
| Total other income, net | 10,245 | 1,370 | 10,805 | 4,995 | ||||||||||||
| Net loss | $ | (44,491 | ) | $ | (33,475 | ) | $ | (142,270 | ) | $ | (106,611 | ) | ||||
| Cumulative dividends on convertible preferred stock | — | (10,395 | ) | (32,181 | ) | (30,360 | ) | |||||||||
| Deemed dividend upon down-round of convertible preferred stock | — | — | (7,875 | ) | — | |||||||||||
| Net loss allocable to common stockholders | $ | (44,491 | ) | $ | (43,870 | ) | $ | (182,326 | ) | $ | (136,971 | ) | ||||
| Net loss per share allocable to common stockholders, basic and diluted | $ | (0.36 | ) | $ | (21.66 | ) | $ | (3.51 | ) | $ | (67.78 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 123,593,149 | 2,025,284 | 51,962,288 | 2,020,689 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (44,491 | ) | $ | (33,475 | ) | $ | (142,270 | ) | $ | (106,611 | ) | ||||
| Unrealized gains (losses) on marketable securities | (1,895 | ) | — | (1,913 | ) | (21 | ) | |||||||||
| Comprehensive loss | $ | (46,386 | ) | $ | (33,475 | ) | $ | (144,183 | ) | $ | (106,632 | ) | ||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Parabilis Medicines report for third-quarter 2026 earnings?
Parabilis reported $2.114 million in revenue and a $44.491 million net loss for the quarter ended September 30, 2026. The comparable 2025 quarter had no revenue and a $33.475 million net loss.
When does Parabilis plan to start the zolucatetide PEDESTAL Phase 3 trial?
Parabilis plans to initiate the desmoid tumor PEDESTAL trial in the first half of 2027, with topline results anticipated in 2029. The planned global study is randomized and double-blind, following alignment with the FDA on dose, regimen and trial design.